View Future GrowthBiotoxtech 과거 순이익 실적과거 기준 점검 1/6Biotoxtech 의 수입은 연평균 -46.5%의 비율로 감소해 온 반면, Life Sciences 산업은 연평균 3.1%의 비율로 감소했습니다. 매출은 연평균 8.8%의 비율로 증가해 왔습니다.핵심 정보-46.49%순이익 성장률-46.93%주당순이익(EPS) 성장률Life Sciences 산업 성장률53.72%매출 성장률8.78%자기자본이익률-7.61%순이익률1.61%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트분석 기사 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩2,630, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 21x in the Life Sciences industry in South Korea. Total loss to shareholders of 68% over the past three years.공시 • Mar 17Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: sky garden hall, 5806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩44.8b market cap, or US$30.6m).Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩3,190, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 62% over the past three years.New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩42.6b market cap, or US$29.3m).분석 기사 • Sep 01Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) is definitely...공시 • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.공시 • Mar 15Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩53.7b market cap, or US$37.4m).분석 기사 • Oct 21Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetBiotoxtech Co., Ltd.'s ( KOSDAQ:086040 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...공시 • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.New Risk • Nov 28New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩95.1b market cap, or US$73.4m).New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (65% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩123.1b market cap, or US$95.0m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,110, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.6% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩8,990, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past three years.공시 • Aug 25Biotoxtech Co., Ltd. announced that it has received KRW 18 billion in funding from BNK Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd. and other investorsOn August 24, 2021, Biotoxtech Co., Ltd. closed the transaction.공시 • Aug 21Biotoxtech Co., Ltd. announced that it expects to receive KRW 18000 billion in funding from BNK Securities Co., Ltd., Investment ArmBiotoxtech Co., Ltd.분석 기사 • May 06Is Biotoxtech (KOSDAQ:086040) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Mar 28Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)Today we will run through one way of estimating the intrinsic value of Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) by...분석 기사 • Feb 20Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?Some Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) shareholders are probably rather concerned to see the share price fall 32...Is New 90 Day High Low • Feb 18New 90-day low: ₩11,200The company is down 29% from its price of ₩15,700 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.분석 기사 • Jan 24Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?Most readers would already be aware that Biotoxtech's (KOSDAQ:086040) stock increased significantly by 15% over the...분석 기사 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩16,700, the stock is trading at a trailing P/E ratio of 57.4x, down from the previous P/E ratio of 68.9x. This compares to an average P/E of 62x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 127%.분석 기사 • Nov 30Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 15% share price gain to ₩20,300, the stock is trading at a trailing P/E ratio of 69.7x, up from the previous P/E ratio of 60.4x. This compares to an average P/E of 102x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 150%.Is New 90 Day High Low • Nov 19New 90-day high: ₩16,050The company is up 59% from its price of ₩10,100 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day high: ₩14,200The company is up 42% from its price of ₩9,970 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.매출 및 비용 세부 내역Biotoxtech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A086040 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2647,63676910,39166731 Dec 2547,0171,16310,24864330 Sep 2544,1908799,22754630 Jun 2543,411-5,8289,56862231 Mar 2543,601-6,6129,99692731 Dec 2441,341-6,4279,62369430 Sep 2438,445-4,4109,85976030 Jun 2434,475-4,9439,31152931 Mar 2433,604-5,4198,63827331 Dec 2332,631-4,8789,04245430 Sep 2334,216-5,40810,24133230 Jun 2336,638-2,48710,43433231 Mar 2337,00619910,6827231 Dec 2237,2921,27810,833030 Sep 2236,2635,6848,417030 Jun 2235,4615,9107,567031 Mar 2233,9766,4626,425031 Dec 2132,7176,8325,464030 Sep 2131,1203,5265,116030 Jun 2128,5702,6335,135031 Mar 2127,2893,5505,724031 Dec 2026,4292,6145,413030 Sep 2026,3064,2375,135030 Jun 2025,9672,4265,358031 Mar 2025,679-1,4145,086031 Dec 1925,854-1,4825,056030 Sep 1922,105-4,9132,770-15330 Jun 1923,979-1,5483,526-15331 Mar 1926,632244,829-8831 Dec 1827,2454,1315,100030 Sep 1831,5675,2619,27023530 Jun 1829,9853,7358,54123531 Mar 1827,0594,8877,06517031 Dec 1725,5651,3926,2978330 Sep 1724,3302,1154,795030 Jun 1723,9921,9664,560031 Mar 1723,1961,5844,468031 Dec 1622,2571,0454,915030 Sep 1620,404-1,1736,225-1030 Jun 1618,932-1,9426,051231 Mar 1617,932-2,8736,3491231 Dec 1516,676-3,9056,4382330 Sep 1515,384-3,7905,2803130 Jun 1515,044-4,5395,47231양질의 수익: A086040는 ₩7.8B 규모의 큰 일회성 이익이 있어 31st March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: A086040는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A086040의 수익은 지난 5년 동안 연평균 46.5% 감소했습니다.성장 가속화: A086040는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: A086040는 지난해 흑자전환하여 지난 해 수익 성장률을 Life Sciences 업계(-26.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A086040의 자본 수익률(-7.6%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/15 13:14종가2026/06/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biotoxtech Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Young Ok KimDAOL Investment & Securities Co., Ltd.Seung-Ho LeeiM Securities
분석 기사 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩2,630, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 21x in the Life Sciences industry in South Korea. Total loss to shareholders of 68% over the past three years.
공시 • Mar 17Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: sky garden hall, 5806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩44.8b market cap, or US$30.6m).
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩3,190, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 62% over the past three years.
New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩42.6b market cap, or US$29.3m).
분석 기사 • Sep 01Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) is definitely...
공시 • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
공시 • Mar 15Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩53.7b market cap, or US$37.4m).
분석 기사 • Oct 21Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetBiotoxtech Co., Ltd.'s ( KOSDAQ:086040 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...
공시 • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
New Risk • Nov 28New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩95.1b market cap, or US$73.4m).
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (65% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩123.1b market cap, or US$95.0m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,110, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.6% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩8,990, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past three years.
공시 • Aug 25Biotoxtech Co., Ltd. announced that it has received KRW 18 billion in funding from BNK Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd. and other investorsOn August 24, 2021, Biotoxtech Co., Ltd. closed the transaction.
공시 • Aug 21Biotoxtech Co., Ltd. announced that it expects to receive KRW 18000 billion in funding from BNK Securities Co., Ltd., Investment ArmBiotoxtech Co., Ltd.
분석 기사 • May 06Is Biotoxtech (KOSDAQ:086040) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Mar 28Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)Today we will run through one way of estimating the intrinsic value of Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) by...
분석 기사 • Feb 20Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?Some Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) shareholders are probably rather concerned to see the share price fall 32...
Is New 90 Day High Low • Feb 18New 90-day low: ₩11,200The company is down 29% from its price of ₩15,700 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.
분석 기사 • Jan 24Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?Most readers would already be aware that Biotoxtech's (KOSDAQ:086040) stock increased significantly by 15% over the...
분석 기사 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩16,700, the stock is trading at a trailing P/E ratio of 57.4x, down from the previous P/E ratio of 68.9x. This compares to an average P/E of 62x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 127%.
분석 기사 • Nov 30Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 15% share price gain to ₩20,300, the stock is trading at a trailing P/E ratio of 69.7x, up from the previous P/E ratio of 60.4x. This compares to an average P/E of 102x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 150%.
Is New 90 Day High Low • Nov 19New 90-day high: ₩16,050The company is up 59% from its price of ₩10,100 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day high: ₩14,200The company is up 42% from its price of ₩9,970 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.